PAHC stock sentiment todayPhibro Animal Health Corp
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
PAHC
Phibro Animal Health CorpStrategic acquisition of Zoetis’s medicated feed additive portfolio is a transformative catalyst for market share and margin expansion.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for PAHC. Not financial advice.
Price · last 12 months
Gossip
Market sentiment is highly positive following the definitive agreement to acquire Zoetis’s MFA and water-soluble product portfolio for $350M. Analysts view this as a legacy-defining move that consolidates Phibro's leadership in the livestock health space.
- ·Zoetis asset acquisition synergy
- ·Expansion in emerging markets (Brazil/SE Asia)
- ·Strong demand for nutritional specialties
Financial
Phibro shows robust revenue growth in its Animal Health segment, though leverage will increase temporarily to fund acquisitions. Profitability is improving as product mix shifts toward higher-margin vaccines and nutritional specialties.
- ·P/E Ratio (Forward) ~18.5x
- ·Revenue Growth: Mid-to-high single digits
- ·Dividend Yield: ~1.2%
- ·EBITDA Margin: ~12-14% (expanding post-acquisition)
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders bought a net $318K on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Integration risks associated with the large Zoetis portfolio
- ·Regulatory scrutiny on antimicrobial resistance (AMR) limiting antibiotic use
- ·Foreign exchange headwinds affecting international sales
Peer temperature
How direct competitors stack up against PAHC right now.
- NEUTRALZTSZoetis Inc.
COLDER — trading at a premium P/E of 33x with slower domestic livestock growth compared to PAHC's newly acquired momentum.
See full analysis → - NEUTRALELANElanco Animal Health
COLDER — struggling with higher debt-to-equity ratios and a more volatile product launch pipeline.
See full analysis → - COLDHESAYHeska Corporation (Mars)
COLDER — focus is almost entirely on companion animal diagnostics, missing the current surge in global protein demand favoring PAHC.
See full analysis →
- PAHC+6.2%
- ZTS+1.9%
- ELAN-6.6%
- HESAY-5.6%
Analyst price target
Consensus average of 3 analysts · median 44.00
Source: StockAnalysis.com · updated 2026-09-02
AI-generated analysis for informational purposes only. Not financial advice.